Physician profile
Pardeep Kumari
NPI 1083697320
$3,418.10
in general payments reported to CMS, 2019-2025
25 companies · $700 in 2025
The $700 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $650 · 2020: $134 · 2021: $197 · 2022: $380 · 2023: $636 · 2024: $721 · 2025: $700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,057.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,056.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $925.61 | 2019-2025 | Arikayce, Brinsupri |
| Viiv Healthcare Company | $460.52 | 2019-2025 | Dovato, Cabenuva |
| Merck Sharp & Dohme LLC | $436.79 | 2019-2025 | Zerbaxa, Prevymis, Dificid |
| Paratek Pharmaceuticals, INC. | $246.20 | 2019-2025 | Nuzyra |
| Allergan, INC. | $210.68 | 2019-2020 | |
| Abbvie INC. | $203.08 | 2022-2023 | |
| Melinta Therapeutics, LLC | $144.84 | 2019-2025 | Rezzayo, Kimyrsa |
| Smith+Nephew, INC. | $138.52 | 2023-2025 | Collagenase Santyl, Regranex |
| Amgen INC. | $101.26 | 2024 | Krystexxa |
| Theratechnologies INC. | $74.78 | 2020-2024 | Trogarzo, Egrifta |
| Ferring Pharmaceuticals INC. | $66.52 | 2023-2025 | Rebyota |
| Mayne Pharma Commercial LLC | $62.56 | 2022 | |
| Heraeus Medical, LLC. | $48.00 | 2024 | |
| Urgo Medical North America, LLC | $42.88 | 2023 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap, Urgok2, Drawtex Hydroconductive Wound Dressing With Levafiber 4x4 |
| Tetraphase Pharmaceuticals, INC. | $39.84 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $30.07 | 2023-2024 | Qutenza |
| Octapharma USA, INC. | $29.01 | 2023-2024 | Panzyga |
| Janssen Biotech, INC. | $28.85 | 2019 | |
| La Jolla Pharmaceutical Company | $22.67 | 2025 | Xacduro |
| Solventum Corporation | $20.99 | 2024 | V.A.C. Veraflo |
| Aimmune Therapeutics, INC. | $20.50 | 2024 | |
| Kci USA, INC. | $20.08 | 2023 | Activ.A.C. |
| Organogenesis INC. | $18.22 | 2023 | Puraply |
| Janssen Scientific Affairs, LLC | $14.09 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pardeep Kumari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.